The Ledger

Up to 300 million dollars: that is what a digital physical-therapy company is paying, in cash, for a meditation app that investors once valued at 3 billion dollars. Sword Health, a Portugal-founded virtual musculoskeletal care company last valued at more than 4 billion dollars, has agreed to acquire Headspace, the mental-health and mindfulness platform owned by parent company OrangeDot, according to a material-change filing OrangeDot submitted to the Massachusetts Health Policy Commission on July 22, 2026. The filing describes an all-cash transaction expected to take effect September 14, 2026; trade press citing people familiar with the deal put the price between 200 million and 300 million dollars, a steep comedown for a company Ginger’s 2021 merger had valued near 3 billion dollars. Headspace, which has logged more than 100 million app downloads and offers virtual therapy, psychiatry and behavioral-health coaching alongside its meditation content, is expected to keep operating its existing services; Sword says the deal deepens its push into mental health, where it has already built two AI tools, an employer-facing product called Mind and a direct-to-consumer tool called Dawn, launched in March 2026. It is Sword’s second major acquisition this year after buying digital therapeutics company Kaia Health at a comparable price in January, and comes as Sword’s chief executive has said mental health is a core piece of the company’s plan to go public in 2028. Confidence: High on the deal’s existence, structure and closing date, drawn from the regulatory filing itself. Medium on the 200 million to 300 million dollar price, which neither company has officially confirmed. Sources: Sword Health to acquire Headspace, according to filing, STAT News, Sword Health buys Headspace in $200M to $300M deal, pharmaphorum, Sword Health to acquire Headspace, Healthcare Dive, Sword Health to acquire Headspace in all-cash deal, Fierce Healthcare.

120 million dollars: that is the new war chest behind a hepatitis B drug trying to reach the market before its funding runs out. AusperBio Therapeutics, a San Francisco-based biotech, announced August 27, 2026 it completed a 120 million dollar Series C financing round to push AHB-137, an antisense oligonucleotide therapy for chronic hepatitis B, into a Phase 3 registrational program and toward possible commercialization. An unnamed strategic investor led the round, joined by new investor RA Capital Management alongside existing backers HanKang Capital, Qiming Venture Partners and CDH Investments; the proceeds will also advance AHB-171, a second HBV candidate, and fund combination-therapy research. The round brings AusperBio’s total capital raised since 2024 to 360 million dollars, a sign of how much cash a clinical-stage biotech now needs to reach a pivotal trial in a disease affecting roughly 250 million people worldwide with no approved functional cure. Confidence: High on the deal terms and use of funds, drawn from the company’s own release. Low on AHB-137’s ultimate commercial prospects, which depend on Phase 3 data not yet available. Source: AusperBio Completes $120 Million Series C Financing, PR Newswire.

More than 10,000: that is how many Humana members a dialysis giant is now paid to keep off dialysis. DaVita, the Denver-based kidney care company, announced August 25, 2026 a new value-based partnership with Humana aimed at delaying or preventing dialysis and reducing hospitalizations for more than 10,000 Humana Medicare Advantage members with chronic kidney disease. The arrangement extends DaVita’s shift from a company paid per dialysis treatment to one paid, at least for this population, to keep patients off dialysis altogether, a business model that only works if DaVita can manage kidney disease upstream cheaply enough to profit from a shared-savings or capitated arrangement with the insurer. Neither company disclosed the financial structure of the partnership, including whether DaVita bears downside risk if costs run over target. Confidence: High on the partnership’s existence and member count, drawn from DaVita’s own announcement. Low on the underlying financial terms, which were not disclosed. Source: DaVita press release, DaVita Newsroom.

149 percent: that is the year-over-year revenue growth rate behind a background-check startup’s new funding, most of it fueled by employers, including healthcare organizations, that got burned after they stopped watching an employee the day after hiring them. Yardstik, a Minneapolis-based workforce-screening company, announced August 27, 2026 it raised 30 million dollars in Series B funding led by Harbert Growth Partners, with Rally Ventures, MissionOG, Crosslink Capital and Grotech Ventures also participating, bringing its total raised to 65 million dollars. Yardstik’s platform combines background checks with continuous post-hire monitoring, including motor-vehicle record checks, license and certification-expiration alerts, and monitoring against the federal List of Excluded Individuals and Entities, the roster of people and companies barred from billing Medicare and Medicaid; the company counts healthcare organizations among its customers alongside staffing, gig-economy and transportation firms. Confidence: High on the funding terms and investor list, drawn from the company’s own release. Source: Yardstik Raises $30M in Series B, PR Newswire.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Headspace (OrangeDot)	Sword Health	Digital health, behavioral health/mental health platform consolidation	$200 million to $300 million (unconfirmed), all-cash; filed July 22, 2026, expected to close September 14, 2026	Sword Health to acquire Headspace, according to filing, STAT News
AusperBio Therapeutics	Unnamed strategic investor (led), RA Capital Management, HanKang Capital, Qiming Venture Partners, CDH Investments	Biotech, hepatitis B therapeutics	$120 million Series C; announced August 27, 2026	AusperBio Completes $120 Million Series C Financing, PR Newswire
Yardstik	Harbert Growth Partners (led), Rally Ventures, MissionOG, Crosslink Capital, Grotech Ventures	Workforce screening/fraud monitoring, healthcare-adjacent	$30 million Series B; announced August 27, 2026	Yardstik Raises $30M in Series B, PR Newswire

This run’s scan of PE Hub, Axios Pro Rata, FTC and DOJ merger actions and state transaction-review dockets over the last 24 to 48 hours found the three transactions above; no new FTC or DOJ healthcare antitrust actions were spotted in this window. A frontier check on the MultiPlan/Claritev antitrust MDL found no ruling or transcript yet posted from the reported August 22 case management conference, so no dedicated story ran on it today. A frontier scan of workers’ compensation medical costs, a Ledger branch not previously in this stack, found no fresh news dated to this window but surfaced NCCI and WorkCompWire as strong recurring primary and trade sources on medical inflation inside workers’ comp claims, added to the stack below.